Serlift, pills 50mg, 28pcs

Composition

1 tab. contains sertraline 50 mg

Pharmacological action

Serlift is an antidepressant, a derivative of naphthylamine. Selective blocker of reverse neuronal serotonin uptake in the brain.

Neuronal uptake of norepinephrine and dopamine is virtually unaffected.

Serlift has no specific affinity for adreno-and m-cholinergic receptors, GABA-receptors, dopamine, histamine, serotonin or benzodiazepine receptors. Does not inhibit MAO.

Causes anorexia, is effective for obsessive states.

Indications

Treatment of depressive states of various origins in patients with mono-and bipolar affective disorders. Prevention of recurrent episodes of depression.

Use during pregnancy and lactation

Adequate and well-controlled studies on the safety of sertraline in pregnancy have not been conducted, so use is possible only in cases where the expected benefit to the mother exceeds the possible risk to the fetus.

It is not known whether sertraline is excreted in breast milk, so it is not recommended to use it during lactation. Separate studies have shown that in children whose mothers received sertraline during breastfeeding, its plasma level is insignificant or not determined, while concentrations in breast milk exceed those in the mother’s blood.

Women of childbearing age should use reliable methods of contraception during sertraline treatment.

No teratogenic or mutagenic effects of sertraline were detected in experimental studies. However, at doses approximately 2.5-10 times higher than the maximum daily clinical dose, sertraline caused a delay in ossification of fetal bone tissue, possibly as a result of the effect on the mother. When sertraline was administered at doses approximately 5 times higher than the maximum clinical dose, a decrease in neonatal survival was observed.

Contraindications

Concomitant use with MAO inhibitors, hypersensitivity to sertraline.

Side effects

From the central nervous system: dizziness, drowsiness, headache, insomnia, fatigue, weakness, tremor; rarely-manic or hypomanic state, anxiety, restlessness, visual disturbances.

From the cardiovascular system: rarely-redness of the skin with a feeling of heat or warmth, palpitation.

From the digestive system: decreased appetite, diarrhea, dry mouth, nausea, stomach or intestinal cramps, flatulence; rarely-constipation, vomiting.

From the side of metabolism: increased sweating.

From the reproductive system: rarely-decreased potency.

Allergic reactions: rarely-fever, skin rash, hives or pruritus.

Interaction

When coumarin derivatives are co-administered with anticoagulants, the prothrombin time is significantly increased.

When used concomitantly, sertraline can displace other drugs from binding to plasma proteins, as a result of which the plasma concentration of the corresponding Active ingredient increases and the risk of side effects increases.

When used concomitantly with drugs that are metabolized with the participation of the CYP2D6 isoenzyme, it is possible to increase the concentration of these drugs in the blood plasma due to inhibition of the CYP2D6 isoenzyme under the influence of sertraline.

With the simultaneous use of MAO inhibitors (including selegiline, moclobemide), serotonin syndrome may develop (hyperthermia, muscle rigidity, myoclonus, as well as manifestations of instability of the mental and physiological state of the body, up to the development of delirium and coma).

When used concomitantly with lithium salts, tremor may increase. When used concomitantly with desipramine, it is possible to increase the concentration of desipramine in blood plasma; with cimetidine, a significant decrease in sertraline clearance is observed.

How to take, course of use and dosage

Serlift is taken orally-50 mg 1 time/day, if necessary, the dose can be increased to 200 mg/day for several weeks.

The effect manifests itself 7 days after the start of treatment, reaching a maximum in 2-3 weeks.

Special instructions

Use with caution in case of drug abuse or dependence on them in the anamnesis, liver function disorders, kidney function disorders, epileptic seizures, weight loss.

It should not be used in patients undergoing electroshock therapy. Sertraline may be used no earlier than 14 days after discontinuation of MAO inhibitors.

Avoid drinking alcohol during the treatment period.

The safety of use in pediatrics has not been established.

Influence on the ability to drive motor vehicles and manage mechanisms

During treatment, you should avoid activities that require increased attention and a high rate of psychomotor reactions.

Form of production

Film-coated tablets

Storage conditions

In a dry place, at a temperature not exceeding 25 °C

Shelf life

3 years

Active ingredient

Sertraline

Conditions of release from pharmacies

By prescription

Dosage form

Tablets